{"product_id":"survodutide","title":"SURVODUTIDE","description":"\u003cp\u003e\u003cmeta charset=\"UTF-8\"\u003eSurvodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim, currently one of the most closely watched compounds in metabolic disease research. Phase 3 clinical trial data from the SYNCHRONIZE-1 trial — published in 2026 — reported sustained weight loss of up to 16.6% over 76 weeks, placing it among the leading compounds in its class.\u003c\/p\u003e","brand":"Peptiva Life","offers":[{"title":"10","offer_id":53299555959078,"sku":null,"price":115.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1014\/3540\/8678\/files\/SURVODUTIDE-10-MG-01_a7db525e-a86e-4e0c-8171-7b7260086b08.jpg?v=1780592507","url":"https:\/\/www.peptiva.life\/es\/products\/survodutide","provider":"Peptiva Life","version":"1.0","type":"link"}